Clinical Trials at Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

As of July 2026, 64 paid clinical trials are recruiting at Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, located at Dan L Duncan Comprehensive Cancer Center at the O'Quinn Medical Tower at Baylor St. Luke's Medical Center, 1919 Old Spanish Trl, Houston, TX 77054, phone (832) 957-6500 in Houston, Texas. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 16, 2026.

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

64 clinical trials at Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

·Clear filters·↓ Download CSV

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

for Recurrent B Acute Lymphoblastic Leukemia

156 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 1 - 21

Code: NCT02981628·Phase 2·Recruiting

Apply to this trial

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

for Acute Leukemia of Ambiguous Lineage

Drug: Venetoclax

112 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 365 Days

Code: NCT06317662·Phase 2·Recruiting

Apply to this trial

A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

for Basal Ganglia Germinoma

92 locations incl. Mobile

Sponsor: Children's Oncology Group

Sex: All·Age: 3 - 29

Code: NCT06368817·Phase 2·Recruiting

Apply to this trial

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

for Recurrent Langerhans Cell Histiocytosis

106 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 180 Days - 22

Code: NCT05828069·Phase 2·Recruiting

Apply to this trial

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

for Ganglioneuroblastoma, Nodular

156 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 30

Code: NCT06172296·Phase 3·Recruiting

Apply to this trial

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

for Low Grade Astrocytoma

Drug: Selumetinib

124 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 2 - 21

Code: NCT04166409·Phase 3·Recruiting

Apply to this trial

A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study

for Hematopoietic and Lymphatic System Neoplasm

76 locations incl. Mesa

Sponsor: Children's Oncology Group

Sex: All·Age: 15 - 20

Code: NCT06410209·Phase 2·Recruiting

Apply to this trial

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

for HER2-positive Metastatic Breast Cancer

37 locations incl. San Francisco

Sponsor: Abramson Cancer Center at Penn Medicine

Sex: All·Age: 18+

Code: NCT06551116·Recruiting

Apply to this trial

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

for Malignant Glioma

Drug: Selinexor

109 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 12 Months - 21

Code: NCT05099003·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

for Stage II Nasopharyngeal Carcinoma AJCC v8

Drug: Nivolumab

76 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 21

Code: NCT06064097·Phase 2·Recruiting

Apply to this trial

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

for Buccal Mucosa Squamous Cell Carcinoma

106 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT04333537·Phase 2, Phase 3·Recruiting

Apply to this trial

A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia

for B Acute Lymphoblastic Leukemia Associated With Down Syndrome

69 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 6 - 39

Code: NCT05702645·Recruiting

Apply to this trial

Molecular Genetics Studies of Cancer Patients and Their Relatives

for Malignant Neoplasm

35 locations incl. Phoenix

Sponsor: City of Hope Medical Center

Sex: All·Age: All ages·Accepts healthy volunteers

Code: NCT04185935·Recruiting

Apply to this trial

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

for Childhood Astrocytoma

20 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 12 Months - 22

Code: NCT06894979·Phase 1·Recruiting

Apply to this trial

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

for Hodgkin Lymphoma in Remission

69 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: All ages

Code: NCT01790152·Recruiting

Apply to this trial

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

for Diffuse Midline Glioma, H3 K27-Altered

34 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 12 Months - 21

Code: NCT04870944·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

for Recurrent Childhood Acute Myeloid Leukemia

19 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 1 - 18

Code: NCT06247787·Phase 1·Recruiting

Apply to this trial

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

for Childhood Fibrolamellar Carcinoma

21 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 1 - 39

Code: NCT06620302·Phase 1, Phase 2·Recruiting

Apply to this trial

Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy

for Malignant Solid Neoplasm

36 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT05642611·Phase 3·Recruiting

Apply to this trial

A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma

for Cardiovascular Disorder

31 locations incl. Mobile

Sponsor: Children's Oncology Group

Sex: All·Age: 7+

Code: NCT05705531·Recruiting

Apply to this trial

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

for Colorectal Carcinoma

21 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 12 Months - 30

Code: NCT04851119·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients

for Hematopoietic and Lymphoid Cell Neoplasm

29 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 2 - 18

Code: NCT05711667·Phase 3·Recruiting

Apply to this trial

A Study to Give Treatment Inside the Eye to Treat Retinoblastoma

for Bilateral Retinoblastoma

17 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 18

Code: NCT05504291·Phase 2·Recruiting

Apply to this trial

Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Newly Diagnosed, Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

for Desmoplastic Small Round Cell Tumor

28 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 12 - 39

Code: NCT04616560·Phase 1, Phase 2·Recruiting

Apply to this trial